

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/045044 A2

(51) International Patent Classification⁷: C12N 15/19

Basel (CH). SCHERER, Andreas [DE/DE]; Kirchstrasse 11, 79618 Rheinfelden-Herten (DE).

(21) International Application Number:

PCT/EP2004/012572

(74) Agent: GRUBB, Philipp; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date:

5 November 2004 (05.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/518,073 7 November 2003 (07.11.2003) US
60/572,247 18 May 2004 (18.05.2004) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BOLLEKENS, Jacques [BE/BE]; 6, Avenue du Lothier, B-1150 Bruxelles (BE). CHIBOUT, Salah-Dine [FR/FR]; 5, route de Mulhouse, F-68720 Tagolsheim (FR). VONDERSCHER, Jacky [FR/US]; 11 Davenport Street, Cambridge, MA 02140 (US). LEGAY, François [FR/FR]; 8 bis, rue Gambetta, F-68300 Saint Louis (FR). CORDIER, André [BE/CH]; Schweizergasse 33, CH-4054 Basel (CH). PAPOIAN, Ruben [US/CH]; Güterstrasse 43, CH-4053

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS

(57) Abstract: A discovery process beginning with an *in vivo* screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates *in vivo* profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants.

WO 2005/045044 A2